Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2016

01-01-2016 | Original Article

Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2

Authors: Wei Wang, Xiaofei Ren, Yi Cai, Lihong Chen, Weiping Zhang, Jianming Xu

Published in: Digestive Diseases and Sciences | Issue 1/2016

Login to get access

Abstract

Background and Aim

Previous studies have shown that rifampicin induced choleresis, the mechanisms of which have not been described. The aim of this study was to investigate the mechanisms underlying in vivo rifampicin-induced choleresis.

Methods

In one experimental set, rats were treated chronically with rifampicin on days 1, 3 and 7. Serum and biliary parameters were assayed, and mRNA and protein levels, as well as the locations of the hepatic export transporters were analyzed by real-time PCR, western blot and immunofluorescence. Ductular mass was evaluated immunohistochemically. In another experimental set, rats received an acute infusion of rifampicin. The amount of rifampicin in bile was detected using HPLC. Biliary parameters were monitored following intrabiliary retrograde fluxes of the Cl/HCO3 exchange inhibitor 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) or 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB) in the infused rats.

Results

Biliary bicarbonate output increased in parallel to the augmented bile flow in response to rifampicin, and this effect was abolished with intrabiliary administration of DIDS, but not NPPB. The biliary secretion of rifampicin with increases in bile flow and biliary rifampicin in response to different infused doses of the antibiotic show no significant correlations. After rifampicin treatment, the expression level of anion exchanger 2 (AE2) increased, while the location of hepatic transporters did not change. However, RIF treatment did not increase ductular mass significantly.

Conclusions

These results indicate that the increase in bile flow induced by rifampicin is mainly due to increased HCO3 excretion mediated by increased AE2 protein expression and activity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Veggi LM, Crocenzi FA, Roma MG, Mottino AD. Dapsone impairs the bile salt-independent fraction of bile flow in rats: possible involvement of its N-hydroxylated metabolite. Toxicology. 2005;211:97–106.CrossRefPubMed Veggi LM, Crocenzi FA, Roma MG, Mottino AD. Dapsone impairs the bile salt-independent fraction of bile flow in rats: possible involvement of its N-hydroxylated metabolite. Toxicology. 2005;211:97–106.CrossRefPubMed
2.
go back to reference Matsumoto K, Imasato M, Yamazaki Y, et al. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. Gastroenterology. 2014;147:1134–1145.CrossRefPubMed Matsumoto K, Imasato M, Yamazaki Y, et al. Claudin 2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. Gastroenterology. 2014;147:1134–1145.CrossRefPubMed
3.
go back to reference Gerloff T, Stieger B, Hagenbuch B, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273:10046–10050.CrossRefPubMed Gerloff T, Stieger B, Hagenbuch B, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273:10046–10050.CrossRefPubMed
4.
go back to reference Paulusma CC, van Geer MA, Evers R, et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J. 1999;338:393–401.CrossRefPubMedPubMedCentral Paulusma CC, van Geer MA, Evers R, et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J. 1999;338:393–401.CrossRefPubMedPubMedCentral
5.
go back to reference Meier PJ, Knickelbein R, Moseley RH, Dobbins JW, Boyer JL. Evidence for carrier-mediated chloride/bicarbonate exchange in canalicular rat liver plasma membrane vesicles. J Clin Invest. 1985;75:1256–1263.CrossRefPubMedPubMedCentral Meier PJ, Knickelbein R, Moseley RH, Dobbins JW, Boyer JL. Evidence for carrier-mediated chloride/bicarbonate exchange in canalicular rat liver plasma membrane vesicles. J Clin Invest. 1985;75:1256–1263.CrossRefPubMedPubMedCentral
6.
go back to reference Tabibian JH, Masyuk AI, O’hara SP, Larusso NF, Masyuk TV. Physiology of cholangiocytes. Compr Physiol. 2013;3:541–565.PubMed Tabibian JH, Masyuk AI, O’hara SP, Larusso NF, Masyuk TV. Physiology of cholangiocytes. Compr Physiol. 2013;3:541–565.PubMed
7.
8.
go back to reference González R, Cruz A, Ferrín G, et al. Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. J Hepatobiliary Pancreat Sci. 2011;18:740–750.CrossRefPubMed González R, Cruz A, Ferrín G, et al. Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. J Hepatobiliary Pancreat Sci. 2011;18:740–750.CrossRefPubMed
9.
go back to reference Mita S, Suzuki H, Akita H, et al. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos. 2006;34:1575–1581.CrossRefPubMed Mita S, Suzuki H, Akita H, et al. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos. 2006;34:1575–1581.CrossRefPubMed
10.
go back to reference Byrne JA, Strautnieks SS, Mieli-vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123:1649–1658.CrossRefPubMed Byrne JA, Strautnieks SS, Mieli-vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123:1649–1658.CrossRefPubMed
11.
go back to reference Stieger B, Fattinger K, Madon J, Kullak-ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118:422–430.CrossRefPubMed Stieger B, Fattinger K, Madon J, Kullak-ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118:422–430.CrossRefPubMed
12.
go back to reference Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476–485.CrossRefPubMed Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476–485.CrossRefPubMed
13.
go back to reference Back DJ, Cross KJ, Hiley CR, Yates MS. The effect of rifampicin on liver blood flow, microsomal enzyme activity and bile flow in the rat. Biochem Pharmacol. 1979;28:1293–1296.CrossRefPubMed Back DJ, Cross KJ, Hiley CR, Yates MS. The effect of rifampicin on liver blood flow, microsomal enzyme activity and bile flow in the rat. Biochem Pharmacol. 1979;28:1293–1296.CrossRefPubMed
14.
go back to reference Oliven A, Bassan HM. Effects of rifampin and isoniazid on the isolated perfused rat liver. Chemotherapy. 1986;32:159–165.CrossRefPubMed Oliven A, Bassan HM. Effects of rifampin and isoniazid on the isolated perfused rat liver. Chemotherapy. 1986;32:159–165.CrossRefPubMed
15.
go back to reference Banales JM, Arenas F, Rodriguez-ortigosa CM, et al. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology. 2006;43:266–275.CrossRefPubMed Banales JM, Arenas F, Rodriguez-ortigosa CM, et al. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology. 2006;43:266–275.CrossRefPubMed
16.
go back to reference Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58:1201–1208.CrossRefPubMedPubMedCentral Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58:1201–1208.CrossRefPubMedPubMedCentral
17.
go back to reference Miura T, Kimura N, Yamada T, et al. Sustained repression and translocation of Ntcp and expression of Mrp4 for cholestasis after rat 90 % partial hepatectomy. J Hepatol. 2011;55:407–414.CrossRefPubMed Miura T, Kimura N, Yamada T, et al. Sustained repression and translocation of Ntcp and expression of Mrp4 for cholestasis after rat 90 % partial hepatectomy. J Hepatol. 2011;55:407–414.CrossRefPubMed
18.
go back to reference Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology. 2001;33:783–791.CrossRefPubMed Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology. 2001;33:783–791.CrossRefPubMed
19.
go back to reference Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology. 2005;42:420–430.CrossRefPubMed Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology. 2005;42:420–430.CrossRefPubMed
20.
go back to reference Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. PNAS. 2001;98:3369–3374.CrossRefPubMedPubMedCentral Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. PNAS. 2001;98:3369–3374.CrossRefPubMedPubMedCentral
21.
go back to reference He M, Zhang S, Jiao Y, et al. Effects and mechanisms of rifampin on hepatotoxicity of acetaminophen in mice. Food Chem Toxicol. 2012;50:3142–3149.CrossRefPubMed He M, Zhang S, Jiao Y, et al. Effects and mechanisms of rifampin on hepatotoxicity of acetaminophen in mice. Food Chem Toxicol. 2012;50:3142–3149.CrossRefPubMed
22.
go back to reference Hosagrahara V, Reddy J, Ganguly S, et al. Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur J Pharm Sci. 2013;49:33–38.CrossRefPubMed Hosagrahara V, Reddy J, Ganguly S, et al. Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur J Pharm Sci. 2013;49:33–38.CrossRefPubMed
23.
go back to reference Gonzalez P, Mauriz JL, Jimenez R, Gonzalez-gallego J, Tunon MJ. Choleresis and inhibition of biliary lipid secretion induced by piperacillin in the rat. Clin Exp Pharmacol Physiol. 2002;29:880–884.CrossRefPubMed Gonzalez P, Mauriz JL, Jimenez R, Gonzalez-gallego J, Tunon MJ. Choleresis and inhibition of biliary lipid secretion induced by piperacillin in the rat. Clin Exp Pharmacol Physiol. 2002;29:880–884.CrossRefPubMed
24.
go back to reference Martinez-anso E, Castillo JE, Diez J, Medina JF, Prieto J. Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology. 1994;19:1400–1406.CrossRefPubMed Martinez-anso E, Castillo JE, Diez J, Medina JF, Prieto J. Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology. 1994;19:1400–1406.CrossRefPubMed
25.
26.
28.
go back to reference Turi JL, Jaspers I, Dailey LA, et al. Oxidative stress activates anion exchange protein 2 and AP-1 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2002;283:L791–L798.CrossRefPubMed Turi JL, Jaspers I, Dailey LA, et al. Oxidative stress activates anion exchange protein 2 and AP-1 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2002;283:L791–L798.CrossRefPubMed
29.
go back to reference Zhou C, Tiberi M, Liang B, Alper SL, Baltz JM. HCO3 −/Cl− exchange inactivation and reactivation during mouse oocyte meiosis correlates with MEK/MAPK-regulated Ae2 plasma membrane localization. PLoS One. 2009;4:e7417.CrossRefPubMedPubMedCentral Zhou C, Tiberi M, Liang B, Alper SL, Baltz JM. HCO3 /Cl exchange inactivation and reactivation during mouse oocyte meiosis correlates with MEK/MAPK-regulated Ae2 plasma membrane localization. PLoS One. 2009;4:e7417.CrossRefPubMedPubMedCentral
30.
go back to reference Medina JF, Martinez-anso E, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 1997;25:12–17.CrossRefPubMed Medina JF, Martinez-anso E, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 1997;25:12–17.CrossRefPubMed
31.
go back to reference Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology. 1993;105:572–578.PubMed Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology. 1993;105:572–578.PubMed
32.
go back to reference Banales JM, Saez E, Uriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56:687–697.CrossRefPubMedPubMedCentral Banales JM, Saez E, Uriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56:687–697.CrossRefPubMedPubMedCentral
33.
go back to reference Salas JT, Banales JM, Sarvide S, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134:1482–1493.CrossRefPubMed Salas JT, Banales JM, Sarvide S, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134:1482–1493.CrossRefPubMed
34.
go back to reference Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol. 1985;28:475–477.CrossRefPubMed Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol. 1985;28:475–477.CrossRefPubMed
35.
go back to reference Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36:216–220.CrossRefPubMed Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36:216–220.CrossRefPubMed
36.
go back to reference Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077–2080.PubMed Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077–2080.PubMed
37.
go back to reference Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–493.PubMed Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–493.PubMed
38.
go back to reference Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574–576.CrossRefPubMed Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574–576.CrossRefPubMed
39.
go back to reference Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol. 1998;93:1510–1517.PubMed Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol. 1998;93:1510–1517.PubMed
40.
go back to reference Hohenester S, Wenniger LM, Paulusma CC, et al. A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012;55:173–183.CrossRefPubMed Hohenester S, Wenniger LM, Paulusma CC, et al. A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012;55:173–183.CrossRefPubMed
Metadata
Title
Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2
Authors
Wei Wang
Xiaofei Ren
Yi Cai
Lihong Chen
Weiping Zhang
Jianming Xu
Publication date
01-01-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3850-2

Other articles of this Issue 1/2016

Digestive Diseases and Sciences 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine